REPLIGEN CORP Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss
REPLIGEN CORP (RGEN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss of $2.00 thousand as of 2017-03-31, per its 10-Q filed 2017-05-04.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss · last filed 2017-05-04
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $2.00K.
- 2016-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $7.00K.
- 2016-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $1.00K.
- 2016-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $3.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2017-03-31 | $2.00K 10-Q · filed 2017-05-04 |
| 2016-12-31 | $7.00K 10-K · filed 2017-02-23 |
| 2016-09-30 | $1.00K 10-Q · filed 2016-11-03 |
| 2016-03-31 | $3.00K 10-Q · filed 2016-05-05 |
| 2015-12-31 | $19.00K 10-K · filed 2016-02-25 |
| 2015-09-30 | $1.00K 10-Q · filed 2015-11-05 |
| 2015-06-30 | $4.00K 10-Q · filed 2015-08-06 |
| 2015-03-31 | $2.00K 10-Q · filed 2015-05-08 |
| 2014-12-31 | $9.40K 10-K · filed 2015-03-17 |
| 2014-09-30 | $7.60K 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |